News

January 25, 2018

Yervoy Approved in Europe to Treat Pediatric Patients with Advanced Melanoma

News

The European Commission approved Yervoy (ipilimumab) for treating advanced melanoma in pediatric patients ages 12 and older, Bristol-Myers Squibb (BMS) recently announced. This marks Yervoy as BMS’ first immuno-oncology medicine approved in ... Read more

January 24, 2018

Celgene’s $9B Buyout of Juno to Boost Company’s Immuno-Oncology Portfolio

News

Celgene says it will buy Juno Therapeutics for $9 billion in a deal that could make Celgene a world leader in immuno-oncology treatments. Specifically, the Jan. 22 deal gives the New Jersey-based ... Read more

January 23, 2018January 23, 2018

Keytruda Slows Liver Cancer Progression in Phase 2 Trial

News

A study of Keytruda (pembrolizumab) in patients with a difficult-to-treat type of liver cancer suggests that the treatment may extend the time before their disease progresses. Data presented at the ... Read more

January 22, 2018

Rare Melanoma Responds Well to Immunotherapy Despite Thoughts It Wouldn’t, Study Reports

News

A rare type of malignant melanoma is treatable with immunotherapies, according to a new study — overturning previous beliefs that the cancer, called desmoplastic melanoma, is not treatable with such medications. ... Read more

January 19, 2018January 19, 2018

Digital Map of T-cell Receptors Could Help Predict Cancer Patient Responses to Immunotherapy

News

Scientists at Johns Hopkins have created a digital map that addresses the variability of T-cell receptors, the chemical “antennas” that recognize antigens and trigger an immune response. While still under development, ... Read more

January 18, 2018

Phase 1/2a Trial Testing VBI-1901 in Glioblastoma Mulitforme Doses First Patient

News

The Phase 1/2a clinical trial evaluating VBI Vaccines‘ cancer vaccine, VBI-1901, in recurrent glioblastoma multiforme (GBM) has dosed its first patient, the company announced. This follows the clearance of an Investigative New ... Read more

January 17, 2018January 17, 2018

Providence Cancer Institute, Nanobiotix Partner for Preclinical Study of NBTXR3 in Pancreatic Cancer

News

A preclinical study testing Nanobiotix’s radiotherapy enhancer NBTXR3 in pancreatic cancers is underway as part of a collaboration with one of the world’s leading oncological research centers, the Providence Cancer Institute, ... Read more

January 16, 2018

Incysus Seeks OK to Begin Phase 1 Trial of Gamma-delta T-cell Immunotherapy for Glioblastoma

News

Incysus has submitted its second investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of its gamma-delta T-cell immunotherapy candidate ... Read more

January 15, 2018

Inovio and Parker Institute to Collaborate on Bladder Cancer Immunotherapies

News

Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy will collaborate on combination therapies for muscle-invasive bladder cancer. They will use Inovio’s ASPIRE immunotherapy platform to develop the immuno-oncology combo regimens. The ... Read more

January 12, 2018January 12, 2018

Certain Types of Gut Bacteria May Increase Immunotherapy’s Effectiveness in Treating Melanoma, Study Finds

News

Specific bacterial strains in the gut may contribute to the effectiveness of immunotherapy in advanced melanoma, new research from The University of Chicago Medicine shows. The research, titled, “The commensal microbiome is ... Read more